The complaint evaluation included a review of data and information provided by the customer, search for similar complaints, ticket trending review, labeling review, device history record review and field data of alinity i anti-hcv reagent lot 40373be01.The evaluation of complaint data for the product and likely cause alinity i anti-hcv reagent lot 40373be01 identified as expected.Trending review determined no adverse trend for the issue for the product.The ticket trending review of at least 12 months complaint data for the likely cause list number does not identify any adverse or non-statistical trend.Device history record review did not identify any non-conformances or deviations with the complaint lot and complaint issue.The return specimen was tested with a retained kit of alinity i anti-hcv reagent lot number 40373be01.Reactive results (2.33 s/co/ 2.00 s/co/ 2.11 s/co) were obtained.Further mikorgen recomline hcv igg testing was performed.Two weak bands (ns3 and helicase) with intensity below the cut off were identified.The interpretation is negative.Historical performance of the alinity i anti-hcv reagents in the field using data gathered via abbottlink from customers worldwide.The number of standard deviations to the cut-off for the negative populations and the median values, determined the likely cause lots are within their established limits.A review of the manufacturing documentation did not identify any issues associated with the customer¿s observation.There was no issue with reagent performance identified.A review of the product labeling concluded that the issue is sufficiently addressed.Based on the investigation no product deficiency was identified for the alinity i anti-hcv reagent lot number 40373be01.
|